Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05077280 · ClinicalTrials.gov registry record · Phase 2
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by California Pacific Medical Center Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05077280 is a Phase 2 study of Uveal Melanoma that is actively recruiting participants, run by California Pacific Medical Center Research Institute. The registered enrollment target is 40 participants, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05077280, a Phase 2 study of Uveal Melanoma, is actively recruiting participants, sponsored by California Pacific Medical Center Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for two years
Conditions Studied
Interventions
- DRUG Immunotherapy
- RADIATION stereotactic body radiotherapy
Study Locations (1)
California
- California Pacific Medical Center Research Institute - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05077280
The ClinicalTrials.gov registry entry for NCT05077280 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 144-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (72% lower). The listed sponsor is California Pacific Medical Center Research Institute, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Immunotherapy is the first listed.
NCT05077280 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05077280 about?
NCT05077280 is a clinical study titled "A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma". This is a phase 2 trial of concurrent stereotactic radiation therapy (SBRT) with immunotherapy with relatlimab and nivolumab for up to two years. SBRT will be given in three doses of 15Gy each to 1-5 separate metastases. Opdualag (nivolumab 480mg and relatlimab 160mg) will be given every 4 weeks for...
What is the current status of trial NCT05077280?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-09-20. Estimated completion is 2026-03.
What conditions does trial NCT05077280 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT05077280?
The interventions under investigation include: Immunotherapy (DRUG), stereotactic body radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT05077280?
This trial is sponsored by California Pacific Medical Center Research Institute, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05077280 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.